mRNA Stability via EDTA Chelation and Analytical Characterization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The inherent instability of mRNA due to its chemical structure and susceptibility to environmental stressors poses challenges in maintaining the integrity and stability of mRNA therapeutics, necessitating effective methods for evaluating critical quality attributes (CQAs) and minimizing degradation during manufacturing, storage, and exposure to conditions like heat.
Innovation Solution
A comprehensive analytical approach using ion-paired reverse-phase liquid chromatography, size exclusion chromatography, and multi-angle light scattering (MALS) to determine mRNA purity, size distribution, and integrity of 5′ cap and 3′ poly(A) tail, coupled with enzymatic digestion and oligo(dT) affinity capture, to evaluate CQAs under stress conditions, and the use of EDTA to inhibit degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If mRNA is stored under normal conditions, then it maintains reasonable stability, but it still degrades over time due to chemical instability and environmental stressors
Solution Approach 1:
The patent applies parameter changes by modifying storage temperature conditions and adjusting formulation parameters (pH, ionic strength, metal ion chelation) to slow mRNA degradation. The forced degradation studies systematically vary these parameters to identify optimal storage conditions that extend shelf life while maintaining mRNA integrity.
Solution Approach 2:
The patent uses EDTA as an intermediary chelating agent that binds to divalent metal ions (Mg2+, Ca2+) that catalyze mRNA hydrolysis. This intermediary substance removes the harmful metal ions from the system, thereby protecting mRNA from metal-catalyzed degradation and extending its stability during storage.
2Measurement precision
If comprehensive analytical methods are implemented to evaluate mRNA CQAs, then measurement precision improves, but device complexity and manufacturing cost increase
Solution Approach 1:
The patent segments the comprehensive CQA evaluation into distinct analytical modules: IPRP-HPLC for purity and fragmentation analysis, SEC-MALS for size distribution and aggregate characterization, and enzymatic assays for cap and poly(A) tail integrity. This segmentation allows each technique to be optimized independently and facilitates systematic implementation.
Solution Approach 2:
The patent develops a universal analytical platform that combines multiple techniques (chromatography, light scattering, enzymatic analysis) into an integrated workflow capable of assessing all critical quality attributes. This multi-functional approach ensures comprehensive evaluation while maintaining consistency across different mRNA products.
3Reliability
If forced degradation studies are conducted to evaluate mRNA robustness, then reliability of stability-indicating methods improves, but loss of time and productivity decrease
Solution Approach 1:
The patent performs preliminary forced degradation studies under aggressive stress conditions (heat, pH extremes, metal ions) to identify degradation pathways and establish robustness data before routine stability testing. This preliminary action provides early warning signals and validates analytical methods, allowing for more efficient long-term stability studies.
Solution Approach 2:
The patent employs accelerated degradation conditions that rapidly induce mRNA breakdown, allowing quick identification of degradation mechanisms and method validation. By skipping through aggressive stress conditions that would normally take years to observe naturally, the patent achieves rapid reliability assessment of stability-indicating methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a robust and sensitive assessment of mRNA stability and integrity, enabling rapid detection of impurities and degradation pathways, and significantly reduces mRNA breakdown by chelating divalent metals, ensuring the quality and efficacy of mRNA therapeutics.
Implementation Method 1
The presence of divalent metals can accelerate RNA degradation by catalyzing hydrolysis of the sugar-phosphate backbone. EDTA, a chelating agent, binds to these divalent metal ions, removing them from the solution and thereby preventing them from catalyzing the degradation reaction.
Implementation Method 2
multi-angle light scattering (MALS) to determine the molar mass of the SEC eluted sample
Implementation Method 3
determining the purity of the mRNA contained in the sample using ion-paired reverse-phase (IPRP) liquid chromatography
Implementation Method 4
determining the size distribution of the mRNA contained in the sample using size exclusion chromatography (SEC) for separation of different size molecules
Data Source
AI summary
The present inventions provide a concise panel of chromatography-based stability-indicating methods for evaluating in vitro transcribed (IVT) mRNA under various conditions, including varying types and degrees of stress conditions, as part of a forced degradation study. The inventions also provide that addition of EDTA to the mRNAs prior to heat exposure reduces the extent of mRNA degradation, that the transcripts are fragmenting via a divalent metal-ion mediated pathway. The inventions also provide the application of the methods to evaluate the critical quality attributes (CQAs) of mRNAs as well as to detect intrinsic process and product related impurities.